Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028430 | 0.76 | MEN1 (0.49) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL12584926 | 0.75 | KMT2A (0.55) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL4072664 | 0.71 | PKM (0.50) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL4077040 | 0.71 | PKM (0.50) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL4072666 | 0.71 | PKM (0.50) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL12566589 | 0.69 | HPGD (0.60) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL3272443 | 0.67 | FFAR4 (0.70) | PKMMAPTLMNAFFAR4ALDH1A1 | |
| SCHEMBL3243803 | 0.66 | HPGD (0.51) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL3243798 | 0.66 | HPGD (0.51) | MEN1KMT2APKMPOLBHPGD | |
| SCHEMBL4070546 | 0.66 | EGFR (0.60) | MEN1KMT2APKMPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | MEN1 2102/4885KMT2A 4330/4885PKM 1342/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | MEN1 2102/4885KMT2A 4330/4885PKM 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.